PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Shows the trajectory of a company's cash-generation capacity. Consistent growth in operating and free cash flow suggests a robust, self-funding business model—crucial for value investors seeking undervalued, cash-rich opportunities.
5.62%
Net income growth at 50-75% of TRAW's 10.27%. Martin Whitman would worry about lagging competitiveness unless expansions are planned.
3.20%
Less D&A growth vs. TRAW's 33.33%, reducing the hit to reported earnings. David Dodd would confirm that core assets remain sufficient.
No Data
No Data available this quarter, please select a different quarter.
22.07%
SBC growth while TRAW is negative at -100.00%. John Neff would see competitor possibly controlling share issuance more tightly.
81.65%
Well above TRAW's 110.88% if positive yoy. Michael Burry would see a risk of bigger working capital demands vs. competitor, harming free cash flow.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
50.82%
Lower AP growth vs. TRAW's 135.74%, indicating prompt payments. David Dodd would confirm no lost opportunity in interest-free credit if expansions are underfunded.
28.44%
Lower 'other working capital' growth vs. TRAW's 98.55%. David Dodd would see fewer unexpected short-term demands on cash.
-17.77%
Both negative yoy, with TRAW at -205.66%. Martin Whitman would suspect an overall environment of intangible cleanup or shifting revaluations for the niche.
18.75%
Operating cash flow growth at 50-75% of TRAW's 35.21%. Martin Whitman would worry about lagging operational liquidity vs. competitor.
-1425.00%
Negative yoy CapEx while TRAW is 0.00%. Joel Greenblatt would see a near-term FCF boost unless competitor invests for long-term advantage.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-1425.00%
We reduce yoy invests while TRAW stands at 0.00%. Joel Greenblatt sees near-term liquidity advantage unless competitor’s expansions yield high returns.
No Data
No Data available this quarter, please select a different quarter.
-0.29%
Both yoy lines negative, with TRAW at -99.98%. Martin Whitman suspects an environment or preference for internal financing over new equity in the niche.
No Data
No Data available this quarter, please select a different quarter.